CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treated, 83% in the systemic sclerosis group showed clinical response at three months, with all responders maintaining improvements. The therapy was well tolerated with no severe side effects reported. CRISPR plans to continue dose escalation and further trials in autoimmune and immuno-oncology indications.
Following CRISPR Therapeutics' update on their promising gene-edited therapy zugo-cel, the company's stock is performing well on Pluang. As of Nov 08, 2026 23:02 WIB, CRSP shares trade at USD 50.07, up 3.11% for the day, reflecting investor interest in the health sector. The stock's market cap stands at $4.86 billion, with a 52-week range between $44.34 and $61.89, and a typical hold time of 79 days on the platform.
